project id: TCGA-BLCA; case submitter id: TCGA-SY-A9G0; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.17; rna integrity number: 7.8; age at index: 82; days to birth: -30205; days to death: 1008; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Dead; year of birth: 1929; age at diagnosis: 30205; ajcc clinical t: T4; ajcc pathologic m: M0; ajcc pathologic n: N1; ajcc pathologic stage: Stage IV; ajcc pathologic t: T4; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 378.0; icd 10 code: C67.4; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Posterior wall of bladder; synchronous malignancy: Not Reported; tissue or organ of origin: Posterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 0.5342465753424658; pack years smoked: 9.75; is ffpe: false; composition: Not Reported; days to collection: 752; days to sample procurement: 0; initial weight: 50.0; portion submitter id: TCGA-SY-A9G0-01A-12; percent lymphocyte infiltration: 5.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 10.0; percent stromal cells: 25.0; percent tumor cells: 65.0; percent tumor nuclei: 65.0;